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Abstract
Objectives: To determine changes in prescribing patterns in primary care of antipsychotic and mood stabiliser medication
in a representative sample of patients with bipolar disorder in the United Kingdom over a fifteen year period and association
with socio-demographic factors.
Methods: We identified 4700 patients in the Health Improvement Network (THIN) primary care database, who had received
treatment for bipolar disorder between 1995 and 2009. The proportion of time for which each individual was prescribed a
particular medication was studied, along with variation by sex, age and social depravation status (quintiles of Townsend
scores). The number of drugs an individual was taking within a particular year was also examined.
Results: In 1995, 40.6% of patients with bipolar disorder were prescribed a psychotropic medication at least twice. By 2009
this had increased to 78.5% of patients. Valproate registered with the greatest increase in use (22.7%) followed by
olanzapine (15.7%) and quetiapine (9.9%). There were differences by age and sex; with young (18–30 year old) women
having the biggest increase in proportion of time on medication. There were no differences by social deprivation status. By
2009, 34.2% of women of childbearing age were treated with valproate.
Conclusions: Lithium use overall remained relatively constant, whilst second generation antipsychotic and valproate use
increased dramatically. Changes in prescribing practice preceded published trial evidence, especially with the use of second
generation antipsychotics, perhaps with inferences being made from treatment of schizophrenia and use of first generation
antipsychotics. Women of childbearing age were prescribed valproate frequently, against best advice.
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Introduction
Bipolar affective disorder is one of the commonest causes of
disability worldwide, especially within the 15–44 age group [1].
The disorder usually emerges in adolescence or early adulthood,
its most severe form is equally distributed between sexes [2], and
typically follows an unpredictable course. Most treatment
guidelines attempt to inform complex treatment decisions based
on clinical trial findings. In clinical practice, however, patients are
seldom as straightforward as those recruited to trials, in terms of
illness characteristics, diagnostic heterogeneity, labile symptomatic
presentations of the illness, and comorbidity [3]. Whereas most
treatment trials have duration of months, the management of
bipolar disorder is a lifelong effort to reduce symptoms and
maximize quality of life.
Commonly used medications for maintenance treatment of
bipolar disorder are mood stabilisers including lithium and
anticonvulsants (valproate, carbamazepine, lamotrigine), first
generation antipsychotics (FGAs), such as chlorpromazine and
haloperidol, and second generation antipsychotics (SGAs), such as
olanzapine and quetiapine.
There are limited data on the current prescribing patterns in
patients with bipolar disorder in the UK. The evidence for best
maintenance treatment of bipolar disorder is changing and
conflicting [1], [4], [5], [6], and previous studies have shown
substantial variation in prescribing practices [7], [8]. Maintenance
treatments recommended by NICE [4] (which is generally
recognized as producing the gold standard in prescribing
guidelines) are lithium, valproate or olanzapine, and they
recommend prescribing more than one of these medications if
mood stabilization is poor. There are historical data from the
1990s suggesting that prescription patterns changed dramatically
prior to publication of recent randomized controlled trials and
guidelines, with an increase in the prescription of valproate,
carbamazepine and lamotrigine, and a decrease in the use of
lithium during the late 1990s [9], [10].
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Most medication provided to patients with bipolar disorder in
the UK is prescribed by general practitioners, following advice
from secondary services. This has been the case since the mid-
1990s when prescribing budgets were allocated to primary care
services [11]. Therefore we planned to examine prescribing trends
in bipolar disorder over the period 1995 to 2009, by using data
gathered from primary care, which should accurately report
prescribing trends in patients with the disorder.
The aim of this study was to examine changes in prescribing in
the UK for bipolar disorder since the mid 1990s, and to identify
socio-demographic predictors of these prescribing changes. We
hypothesised that commonly used treatment regimens may not
correspond with guidelines produced by NICE [4] or other
advisory bodies [1], [5], [6].
Methods
Study design and setting
We carried out a retrospective cohort study of individuals in
primary care with a diagnosis of bipolar disorder using The Health
Improvement Network (THIN) primary care database.
Data Source
THIN is one of the largest sources of primary care data in the
United Kingdom containing information from over 470 general
practices (accounting for over 9 million patients)(www.epic-uk.org).
In the UK most people with severe mental illness are registered
with primary care [12] and the validity of general practice
computer diagnoses of severe mental illness has been established
previously [13]. The database is broadly representative of UK
general practice consultations and prescribing statistics [14].
THIN contains records of each patient’s medical conditions and
symptoms, recorded during routine consultations and all prescrip-
tions issued by GPs. Symptoms and diagnoses are classified using
the Read code system, a hierarchical recording system used to
record clinical summary information [15]. This creates a
computerized medical history for each patient from the time they
register with a general practice. For this study patients were only
included after the date on which their practice reached an
acceptable standard of data recording [16]. In addition, the
database holds information on basic demographics and social
deprivation (measured using quintiles of Townsend score). The
Townsend score is based on a patient’s postcode, linked to
population census data from 2001 [17]. It is a combined measure
of owner-occupation, car ownership, overcrowding and unem-
ployment [18].
All diagnoses of bipolar disorder were identified by Read codes
in the patient’s clinical records. Oral mood stabilisers and
antipsychotics prescribed in primary care were identified based
on encrypted multilex codes mapped to the British National
Formulary. Both the list of Read codes and drug codes were
created using the method described by Dave & Peterson [19].
The THIN scheme for obtaining and providing anonymous
patient data to researchers was approved by the National Health
Service South-East Multicenter Research Ethics Committee
(MREC) in 2002. The current study was reviewed and approved
by theLondon Research Ethics Committee, reference number:
09/H0718/11.
Participants
Eligible patients were defined as being 18 years or over with at
least one recorded diagnosis of bipolar disorder between 1995 and
2009. Patients were excluded if they had a diagnosis of epilepsy
(identified by Read codes in the patients records), because of the
overlap in prescribing of antiepileptic medications as mood
stabilisers.
Statistical Methods
To explore time trends in prescriptions we first identified
individuals with two or more prescriptions of oral antipsychotic or
mood stabiliser medication, as this would suggest a physician’s
intention to treat with a particular medication and initial patient
concordance. We then analyzed the frequency of prescriptions by
calendar year. We assessed the proportion of time for which each
individual was prescribed a particular medication. This time was
organized into treatment sessions, defined as a period of follow-up
within which drug prescribing was continuous. As has been
suggested previously [20], [21] we defined the end of a treatment
session as a gap of 3 months or more between subsequent
prescriptions. To aid analysis treatment sessions were defined in 3
levels: Level 1 – any antipsychotic prescription or any mood
stabiliser prescription, Level 2 – class of treatment namely first
generation antipsychotic (FGA), second generation antipsychotic
(SGA), anticonvulsant (carbamazepine, lamotrigine, valproate), or
lithium, Level 3 – individual antipsychotic or mood stabiliser
medications. The data were then stratified by sex, age-group and
social deprivation to assess whether each of these variables
influenced any differences in treatment, or time spent in treatment.
Particular attention was paid to subgroups that have been
identified in guidelines as having specific needs/risks associated
with treatment, such as women of childbearing age. To examine
co-prescribing we studied the number of patients in a year issued
two or more prescriptions for two or more psychotropics. All
analysis was conducted using Stata version 11 for Windows.
Results
Sample demographics
There were 5,224 patients diagnosed with bipolar disorder
(2,017 men, 3207 women), 4,700 (90.0%) of whom received at
least two concurrent prescriptions of an oral antipsychotic or
mood stabiliser during the study period. The sample demographics
of the treated and untreated (issued less than two prescriptions)
groups are described in Table 1.
Overall trends
In 1995, 39/96 (40.6%) of patients with bipolar disorder were
prescribed a psychotropic medication at least twice. By 2009 this
had increased to 3037/3870 (78.5%) of patients. The proportion
Table 1. Demographics of the treated and untreated groups.
Treated Untreated (,2 prescriptions)
N 4700 524
Men (%) 1795 (38) 230 (44)
Mean age (S.D) 44.5 (15.2) 39.7 (15.6)
Median Follow-up (IQR) 7.69 (4.5–10.0) 4.98 (2.4–8.3)
Townsend Score (%)
1 (least deprived) 859 (19) 108 (21)
2 797 (18) 100 (20)
3 983 (22) 99 (19)
4 1025 (23) 104 (20)
5 (most deprived) 830 (18) 98 (19)
doi:10.1371/journal.pone.0028725.t001
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of individuals prescribed a medication at least twice rose by a
mean of 2.7% per year.
Table 2 shows the changes in proportion of time spent on
antipsychotic or mood stabiliser medication between 1995 and
2009, by sex, age band and Townsend score.
There was a 26.4% increase in the overall proportion of time
spent on any antipsychotic medication between 1995 (14.2%) and
2009 (40.6%) (Figure 1), and a 29.9% increase in the proportion of
time spent on any mood stabiliser over the same time period
(27.5% to 57.4%) (Figure 2). This increase was larger for women
for both types of medication (antipsychotics; 18.7% increase for
men, 30.7% increase for women, mood stabilisers; 24.1% increase
for men 33.0% increase for women). Some of this difference may
be explained by the rapid increase in proportion of time spent on
medication between 1995 and 1996 in the female group. However
excluding the 1995 data still shows a larger increase for females.
The biggest increase in proportion of time spent on both
antipsychotic medications and mood stabilisers was in the 18–30
age range (34.0% and 32.2% respectively over the study period).
There was no apparent difference between prescribing of
antipsychotics or mood stabilisers by Townsend score (Table 2).
Antipsychotics
In 1995 the proportion of time patients spent on first generation
antipsychotics was 14.2%. By 2009 this had reduced to 6.9%. In
contrast, the proportion of time spent on second generation
antipsychotics had increased from zero to 35.0% (Figure 1).
The most commonly prescribed antipsychotics used for bipolar
disorder in 1995 were 1) chlorpromazine, 2) haloperidol and 3)
trifluoperazine. In 2009 most popular were 1) olanzapine 2)
quetiapine 3) risperidone (Figure 3). Older people (60–75 age
range) spent a greater proportion of time on olanzapine than those
Table 2. Time spent in treatment with antipsychotic and mood stabiliser medication by sex, age group and Townsend score.
ALL ANTIPSYCHOTICS
1995 2009 Difference Proportion
% Total person-years % Total person-years 2009-1995 (%) 2009/1995
Gender
Male 19.8 9.6 38.6 1275.6 18.8 1.9
Female 11.2 18.5 41.9 2056.7 30.7 3.7
Age
18–29 0 3.3 34 239.6 34 *
30–44 17 9.2 38.7 987 21.7 2.3
45–59 16.2 9.2 42.2 1223.9 25.9 2.6
60–75 14.6 6.4 42.5 881.7 27.9 2.9
Deprivation
1 (Least deprived) 11.6 4.7 34.7 621.1 23.1 3
2 9.5 4.1 35.4 595.2 25.9 3.7
3 14.1 4.2 38.6 708.7 24.5 2.7
4 9.8 7.4 45.9 708.9 36 4.7
5 (Most deprived) 24.9 4.0 49.2 568.4 24.2 2
ALL MOOD STABILISERS
1995 2009 Difference Proportion
% Total person-years % Total person-years 2009-1995 (%) 2009/1995
Gender
Male 33.1 9.6 57.2 1275.6 24.1 1.7
Female 24.7 18.5 57.7 2056.7 33 2.3
Age
18–29 8.6 3.3 40.9 239.6 32.2 4.7
30–44 22.9 9.2 52.8 987 29.9 2.3
45–59 29.4 9.2 61.8 1223.9 32.4 2.1
60–75 41.4 6.4 61.3 881.7 19.9 1.5
Deprivation
1 (Least deprived) 23.5 4.7 57.5 621.1 34.1 2.5
2 38.3 4.1 59.4 595.2 21.2 1.6
3 8.6 4.2 56.4 708.7 47.8 6.6
4 40.6 7.4 57.4 708.9 16.8 1.4
5 (Most deprived) 14.5 4.0 56.4 568.4 41.9 3.9
doi:10.1371/journal.pone.0028725.t002
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in younger age groups (18.9% in 2009, compared to 12.4% for
18–30 year olds). This was not observed for other antipsychotic
medications and was reversed for aripiprazole, with patients aged
18–30 years spending more time in treatment (4.3% in 2009
compared to 1.0% in 2009). Men were more likely to spend time
in treatment with olanzapine than women in 2009 (17.3% vs.
14.6%), where as women were more likely to spend time in
treatment with quetiapine than men (11.3% vs. 7.8%) (Figure 3).
There were no apparent differences by Townsend score.
Mood stabilisers
Use of lithium increased from 22.5% in 1995 to 29.3% in 2009
(Figure 2). Over the same period valproate use increased from zero
to 22.7%. The proportion of time men spent on lithium reduced
Figure 1. Proportion of time in treatment with antipsychotic medication.
doi:10.1371/journal.pone.0028725.g001
Figure 2. Proportion of time in treatment with mood stabiliser medication.
doi:10.1371/journal.pone.0028725.g002
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by 3.5% (33.1% in 1995 to 29.6% in 2009), whereas for women
the proportion increased by 12.1% (17.0% to 29.1%). For
valproate the proportion of time spent in treatment increased by
22.8% (0% to 22.8%) and 21.6% (0% to 21.6%) for men and
women respectively (Figure 4). The proportion of time spent on
lithium was greater for older patients, and this was consistent
throughout the study period, such that the mean proportion of
time spent on lithium of different age groups was: 18–29, 12.1%;
30–44, 23.5%; 45–59, 32.4%; 60–75, 42.3% (Figure 5). This trend
was more pronounced for women than men, but was present
in both sexes. There were no apparent differences by Townsend
score.
In 1995 none of the women of childbearing age (18–45 years
old) in our sample were prescribed valproate. By 2009, 233 out of
the 682 women with two or more prescriptions that year were
taking valproate (34.2%) and spent 35.6% of the year in treatment.
Time spent in treatment with carbamazepine increased from
6.5% in 1995 to a peak of 9.5% in 2004; by 2009 this had reduced
to 7.3%. The proportion of time spent in treatment with
lamotrigine increased from zero to 6.2% (Figure 4). Neither of
these drugs showed differences by sex, age or Townsend score.
Co-prescribing
In 1995, 9 out of 39 individuals (23.1%) were issued two or
more prescriptions for more than one psychotropic medication; by
2009 this had increased to 1,461 out of 3,037 (48.1%). In 1995, 7
(17.9%) patients were prescribed lithium and an antipsychotic,
which were all FGAs. In 2009, 665 (21.9%) individuals were
prescribed lithium and a FGA or SGA. In 1995, 2 (5.2%) patients
were prescribed an anticonvulsant (valproate, carbamazepine or
lamotrigine) and an antipsychotic; by 2009 this had increased to
932 (30.7%). Lithium and an anticonvulsant was prescribed to
5.2% of the population (2/39) in 1995, by 2009 this stood at
12.1% (367/3037) (Figure 6).
Over the 15 years of the study, patients prescribed lithium plus
an antipsychotic tended to spend an approximately equal
proportion of time on antipsychotic medication (mean 23.5%) as
those prescribed valproate plus an antipsychotic (mean 25.7%).
Figure 3. Prescribing of the 5 most common antipsychotic medications by sex. A) Male, B) Female.
doi:10.1371/journal.pone.0028725.g003
Figure 4. Prescribing of mood stabilisers by sex. A) Male and B) Female.
doi:10.1371/journal.pone.0028725.g004
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Figure 5. Prescribing by age group. A) First generation antipsychotic, B) Second generation antipsychotic, C) Lithium, D) Anticonvulsant.
doi:10.1371/journal.pone.0028725.g005
Figure 6. Percentage of treated individuals by medication group in A) 1995 and B) 2009*. *Not to scale - 1995 euler diagram should be
approximately 1/80th the size of 2009.
doi:10.1371/journal.pone.0028725.g006
Trends in Prescribing for Bipolar Disorder
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28725
However those on lithium plus an antipsychotic spent a higher
proportion of time taking lithium than the valproate plus
antipsychotic cohort spent taking valproate (means; 60.8% vs.
29.8%).
Discussion
Our results indicate that from 1995 to 2009 prescribing, broadly
speaking, corresponded with availability, licensing and guidelines.
Key findings are: 1) the proportion of patients offered treatment
for bipolar disorder increased markedly between 1995 and 2009;
2) patients spent ever increasing amounts of time on psychotropic
medication, in particular second generation antipsychotics and
valproate; 3) this increase in time on medication was most
noticeable in younger women; 4) antipsychotic and valproate
prescribing increased relative to lithium; 5) use of second
generation antipsychotics accelerated; 6) prescribing more than
one drug at once increased; 7) treatment was not influenced by
social deprivation and; 8) by 2009 one third of women of
childbearing age who took medication for bipolar disorder were
taking valproate. This final finding is worrying as guidelines are
now very clear that valproate should be avoided because of its
teratogenic potential.
The long-term management of bipolar disorder is complex. The
prescribing recommendations described in the 2006 NICE
guidelines [4] should represent the gold standard, but they are
unusually vague and recently a review and update has been
requested [22]. NICE recommends lithium, olanzapine or
valproate as first line, which we have found to be the three most
commonly prescribed psychotropic medications for maintenance.
If the patient has frequent relapses, or symptoms continue to cause
functional impairment, they recommend switching to an alterna-
tive monotherapy or adding a second prophylactic agent (lithium,
olanzapine, valproate). However the evidence supporting the
maintenance use of olanzapine and valproate is limited, and
valproate is not licensed for this use. If anything, the evidence from
research carried out after 2006 further strengthens the argument
for use of lithium first line [1], [23], [24], [25], but the
complications of initiation, monitoring and side effect profile
may continue to limit its use. It is also recognised that irregular use
of lithium produces poor outcomes [26], risk of relapse on
stopping [27] and that less than two years use may have no
beneficial effect [28]. It may therefore be that the degree of
concordance suggested by our findings reduces its benefit relative
to other maintenance medications.
The increase in time spent on medication is likely to represent
both increased prescribing and increased adherence to medication
[20], [29]. Previous studies of antipsychotic prescribing trends
have found that, over time, patients have been prescribed
medications (for all indications) for longer periods [30], and this
has been shown specifically in the bipolar disorder patient group
[31]. Our results differ from some studies from the United States,
which found that lithium prescription for bipolar declined, over
the period 1990–2005 [31], [32], [33]. The latter two studies also
failed to show the increase in antipsychotic prescriptions found in
this study.
It appears that use of second generation antipsychotics for
bipolar disorder pre-empted the available scientific evidence. The
first case reports suggesting the effective treatment of mania with
olanzapine were published in 1997 [34], [35]. These were followed
by the publication of the first randomised control trials in 1999
[36], [37]. Olanzapine was first given marketing authorisation for
psychosis in 1996, and was first used in our cohort in 1997.
Risperidone was first used in our study in 1996, two years before
the first published randomised control trial into its effectiveness as
monotherapy [38], but four years after it was first authorised.
Quetiapine, authorised for schizophrenia initially in 1997, was first
used in our sample in 1998, while the first trial of quetiapine as an
add-on medication was not published until 2004 [39]. However it
does seem reasonable that clinicians made inferences from trials of
second generation antipsychotics in psychosis and clinical
experience of first generation antipsychotics.
Concerns were raised about the teratogenic effects of valproate
in the early 1980s [40], but it was only in 2004 that the risk was
confirmed to be higher than other anticonvulsants [41], [42].
Therefore psychiatrists prescribing in this population may only
have become aware of this risk via the NICE guidelines from 2006
onwards [4]. However, despite this advice, use of valproate has
continued to rise since then.
Previous studies have shown that co-prescribing is common
[43], [44] with up to 80% of patients on a mood stabiliser plus
another medication. In our cohort 48.1% were prescribed more
than one agent in 2009, and an anticonvulsant plus an
antipsychotic became the most commonly used dual therapy.
Co-prescribing, although concordant with guidelines is problem-
atic due to the side effect profiles of the drugs used, and concerns
over long term health risks [1].
Limitations
THIN is a primary care database and, as with all clinical
databases, it is impossible to be sure that a person prescribed a
psychotropic medication was concordant. However, it is fair to
assume that repeat prescription of a particular drug implies
medication collection, from which we may infer some degree of
adherence. Gaps in treatment may be explained by hospital
prescribing, such as during acute inpatient stays, and therefore we
may be underestimating the duration of treatment. Also, there
may be a number of patients who receive all their medication from
secondary care, though these numbers are likely to be small, given
the manner in which prescribing budgets are allocated in the UK.
Secondary care prescribing may have been higher earlier in the
study time frame, but analyzing the results excluding the first 5
years of data does not change the findings. There is no reason to
suppose that any particular group would have been preferentially
prescribed for in secondary rather than primary care. Although
the focus of this study is primary care prescribing, specialist
treatment is likely to be a major influence on GP prescribing, and
so it is likely that these trends would be reflected in the total
population with bipolar disorder.
We were unable to separate bipolar I disorder from bipolar II
disorder in our cohort; however given that treatment guidelines
are the same for both subtypes of the disorder (extrapolated from
research in bipolar I), the trends in prescribing are likely to be very
similar. Changes in diagnostic practice probably mean there was
an increase in the number of bipolar II patients over the study
period. From our current study we are unable to comment on
whether a drug was prescribed initially as a monotherapy or, if
not, in what order it may have been added to the treatment
regimen. We also do not know about historical prescribing for the
cohort so we are unable to state whether clinicians have adhered
to the guidelines for first line drugs on initiation of treatment. 62%
of the treated sample were women, although the overall incidence
in men and women is thought to be equal, it is recognised that
females have more acute episodes of illness [45], and therefore
their information may be better recorded in the database. Our
cohort was also relatively old at the start of follow-up (mean 44.5
years) compared to the observed age of onset of the disorder,
which tends to be in the early twenties [45]. It is likely therefore
Trends in Prescribing for Bipolar Disorder
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that some our sample is previously diagnosed cases that have
entered the database late. It may be that trends in treatment of
newly diagnosed individuals (incident cases) differ from our
findings.
Conclusions
This study identified broad concordance with prescribing
guidelines. Our findings suggest a number of important trends
that should be noted by researchers and clinicians alike, the most
striking being the overall increase in prescribing and time spent in
treatment. A number of questions remain unanswered about the
long-term management of bipolar disorder. Although there is
unlikely to be one ideal treatment for all patients with bipolar
disorder, as the illness is heterogeneous and subtypes appear to be
associated with a preferential response to specific drugs [46],
further studies with long follow-up times are necessary to clarify
the benefits (and risks) of different psychotropic medications,
especially antipsychotics. Despite this it would be useful to
prescribers (both psychiatrists and GPs) if NICE guidelines were
able to be more precise about recommendations, especially in the
areas of first line treatments and treatments for women of
childbearing age. Perhaps there also needs to be more education
about these areas.
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